Worldwide,hepatocellular carcinoma(HCC)is a frequent complication of liver diseases and remains a major cause of cancer-related mortality.In addition,the prevalence of nonalcoholic steatohepatitis(NASH)as prerequisite...Worldwide,hepatocellular carcinoma(HCC)is a frequent complication of liver diseases and remains a major cause of cancer-related mortality.In addition,the prevalence of nonalcoholic steatohepatitis(NASH)as prerequisite of hepatocarcinogenesis,even in the absence of cirrhosis,is rising rapidly.The early detection of HCC has been crucial in improving the survival outcomes of those patients.However,in the mostly obese NASH population,diagnostic sensitivity of ultrasound-based HCC screening approaches is limited.On the other hand,biomarkers for HCC show promising potential to improve early detection,providing reproducible,investigator-independent results that can be used either alone or integrated with other biomarkers for scoring models.In the past,validation has been limited due to a lack of prospective longitudinal cohort studies.At present,large-scale retrospective phase-III-biomarker-development gives hope for the availability of biomarker-based screening approaches in the near future.This review focuses on the potential impact of biomarkers on surveillance strategies,potentially allowing for earlier HCC diagnosis.展开更多
文摘Worldwide,hepatocellular carcinoma(HCC)is a frequent complication of liver diseases and remains a major cause of cancer-related mortality.In addition,the prevalence of nonalcoholic steatohepatitis(NASH)as prerequisite of hepatocarcinogenesis,even in the absence of cirrhosis,is rising rapidly.The early detection of HCC has been crucial in improving the survival outcomes of those patients.However,in the mostly obese NASH population,diagnostic sensitivity of ultrasound-based HCC screening approaches is limited.On the other hand,biomarkers for HCC show promising potential to improve early detection,providing reproducible,investigator-independent results that can be used either alone or integrated with other biomarkers for scoring models.In the past,validation has been limited due to a lack of prospective longitudinal cohort studies.At present,large-scale retrospective phase-III-biomarker-development gives hope for the availability of biomarker-based screening approaches in the near future.This review focuses on the potential impact of biomarkers on surveillance strategies,potentially allowing for earlier HCC diagnosis.
